key: cord-0718232-7k36owrf authors: Wang, Zhongliang; Yang, Bohan; Li, Qianwen; Wen, Lu; Zhang, Ruiguang title: Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China date: 2020-03-16 journal: Clin Infect Dis DOI: 10.1093/cid/ciaa272 sha: 27314482a741e0c2adf4e7ebaeceac5124dd9dfc doc_id: 718232 cord_uid: 7k36owrf BACKGROUND: From December 2019 to February 2020, 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a serious outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China. Related clinical features are needed. METHODS: We reviewed 69 patients who were hospitalized in Union hospital in Wuhan between January 16 to January 29, 2020. All patients were confirmed to be infected with SARS-CoV-2 and the final date of follow-up was February 4, 2020. RESULTS: The median age of 69 enrolled patients was 42.0 years (IQR 35.0-62.0), and 32 patients (46%) were men. The most common symptoms were fever (60[87%]), cough (38[55%]), and fatigue (29[42%]). Most patients received antiviral therapy (66 [98.5%] of 67 patients) and antibiotic therapy (66 [98.5%] of 67 patients). As of February 4, 2020, 18 (26.9%) of 67 patients had been discharged, and five patients had died, with a mortality rate of 7.5%. According to the lowest SpO(2) during admission, cases were divided into the SpO(2)≥90% group (n=55) and the SpO(2)<90% group (n=14). All 5 deaths occurred in the SpO(2)<90% group. Compared with SpO(2)≥90% group, patients of the SpO(2)<90% group were older, and showed more comorbidities and higher plasma levels of IL6, IL10, lactate dehydrogenase, and c reactive protein. Arbidol treatment showed tendency to improve the discharging rate and decrease the mortality rate. CONCLUSIONS: COVID-19 appears to show frequent fever, dry cough, and increase of inflammatory cytokines, and induced a mortality rate of 7.5%. Older patients or those with underlying comorbidities are at higher risk of death. Coronaviruses are enveloped, single-stranded, positive-sense RNA viruses that are phenotypically and genotypically diverse, and widespread in bats around the world. Meanwhile, coronaviruses can also be found in many other species as well, including humans, other mammals, and birds. They may cause respiratory, enteric, hepatic, or neurologic diseases [1, 2] . In humans, there are four prevalent coronaviruses (229E, OC43, NL63, and HKU1), which typically cause common respiratory symptoms. Usually, the symptoms caused by coronaviruses are mild. But, in the past two decades, two other strainssevere acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) had caused two large-scale epidemics, with mortality rates of 10% for SARS-CoV and 37% for MERS-CoV [3] . In late December 2019, a series of cases with respiratory symptoms and typical chest computed X-ray tomography (CT) features were reported in Wuhan, Hubei, China. A previously unknown betacoronavirus was then discovered through the use of full-genome sequencing in samples from these patients, and was believed to be the pathogen of coronavirus disease 2019 (COVID-19) [4, 5] . The new betacoronavirus was named 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and formed another clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily. COVID-19 has caused an outbreak in China since late December 2019 and continues to evolve with the number of suspected cases and deaths increasing daily in and outside of China. We describe the epidemiological, clinical, laboratory, and radiologic features, treatment, and 5 prognosis of patients with confirmed infection of SARS-CoV-2 who were hospitalized in Union Hospital, Wuhan. The difference of clinical features between the SpO2≥90% group and the SpO2<90% group would also been compared. In late December 2019, several hospitals of Wuhan reported clusters of patients with pneumonia of unknown cause, which was identified as SARS-CoV-2 soon after. The local government proclaimed a list of designated hospitals to treat patients infected with SARS-CoV-2, including the Union hospital. Generally, the patients of Union hospital come from all regions of Wuhan, especially the Hankou district. In this program, all consecutive patients with confirmed COVID-19 admitted to the main campus of Union hospital from January 16 to January 29, 2020 were enrolled. All patients with COVID-19 enrolled in this study were diagnosed and admitted in accordance with the guideline of the national health commission of China [6]. The final date of follow-up was February 4, 2020. We reviewed clinical charts, nursing records, laboratory results, and chest CT characteristics for all patients. Epidemiological, clinical, imaging, and serological records and treatment and outcomes data were collected from the electronic medical network of Union hospital. To ensure the accuracy of data, two independent researchers were arranged to review and check the data form. The confirmation of COVID-19 is achieved by RT-PCR detection of throat swab samples of suspected patients. Following the recommendation of China National Center for Disease Control, two target genes were set as described previously [5] , including open reading frame1ab (ORF1ab) and nucleocapsid protein (N), and simultaneously amplified and tested during the real-time RT-PCR assay. Target At the time of admission, all the 69 patients had abnormal chest CT findings. Figure 2 shows a typical evolution of chest CT of COVID-19, which belongs to a 74-year-old female. As shown in Figure 2A , the most common CT manifestation on admission is ground glass density enhancement along the outer bands of both lungs. Several days later, the ground glass opacity began to solidify, as shown in Figure 2B . With the development of disease, the consolidation absorbed gradually, as shown in Figure 2C and 2D. In general, the reabsorption takes much longer than consolidation. Figure 3 showed chest CT images of four patients, A/B in the SpO2≥90% group and C/D in the SpO2<90% group. The opacity area of the ground glass is larger and the consolidation degree is more serious in the SpO2<90% group. Plasma proportion of CD4-positive T lymphocytes, CD8-positive T lymphocytes, and B lymphocytes in patients with COVID-19 was within the normal range. The IL6 and IL10 levels in plasma exceeded the upper limit of normal value in both the SpO2≥90% group and the SpO2<90% group. Notably, the level of IL6 in 7 (100%) of 7 patients in the SpO2<90% group exceeded 20 pg/ml ( Table 3 ). The outcomes of two cases with hemopathy were lost because they were transferred to an infection specialized hospital and out of contact. So, they were not enrolled in the analysis of treatment and prognosis in conditions were met, and the time interval between two RT-PCR assays was at least one day. Further, we evaluated the efficacy of arbidol. Resultly, 12 (33%) of 36 patients had been discharged in the arbidol-treated group, whereas 6 (19%) of 31 patients had been discharged in the arbidol-untreated group. All deaths occurred in the arbidol-untreated group. It appears that Arbidol treatment could improve the discharging rate and decrease the mortality rate ( Table 5 ). The efficiency of antifungal agent and corticosteroids were also analyzed in Supplementary Table 1 and Table 2 . Antifungal agent did not show influence on the outcome of COVID-19 patients. And use of corticosteroids were associated with a higher risk of death. Our experience with these 69 patients confirms that COVID-19 is a kind of epidemic pneumonia with fever, dry cough and fatigue as the most common onset symptoms. Most patients have mild manifestations and excellent prognosis. The elderly and the patients with underlying comorbidities are prone to develop severe condition. From the existing data, human-to-human transmission of SARS-CoV-2 among close contacts has occurred since the middle of December and spread out gradually within a month after that [8] . Although Wuhan, origin of the epidemic, had been blocked since January 23, 2020, the number of patients infected with SARS-CoV-2 still raised rapidly. Based on the imported cases from Wuhan into other cities, the basic reproductive number for SARS-CoV-2 was 2.68. The epidemic doubling time was estimated to be 6.4 days [9] . The Chinese government has taken various measures to control population flow and prevent cross infection. But considering the imbalance between large number of infected patients and limited medical resources in Wuhan, family clustering cases should be worried [10] . There is a certain degree of similarity between 2019-CoV and SARS-CoV. Both of them caused frequent fever, cough, and fatigue, whereas the upper respiratory symptoms like pharyngalgia and rhinorrhea were less common [11, 12] . SARS-CoV targets human angiotensin-converting enzyme 2 (hACE2) and infects intrapulmonary epithelial cells more than cells of the upper airways [13, 14] . MERS-CoV attaches to its receptor, an exopeptidase called dipeptidyl peptidase 4 to infect its host [15] . It appears that SARS-CoV-2 uses the same cellular receptor as SARS-CoV did [16] , so the replication of SARS-CoV-2 is more likely to happen in the lower respiratory tract rather than the throat. This hypothesis may be the reason for the false negative was also reported in two other researches [5, 18] . Given SARS-CoV-2 and SARS-CoV share 75%-80% gene sequence and genomic sequence was detected in the faeces of patients infected with SARS-CoV-2, it is likely that SARS-CoV-2 would infect more than just the respiratory system, which may complicate the treatment and prophylaxis of COVID-19 [16] . to the outcomes data of two patients in the SpO2<90% group was missing, the prognosis comparation between the SpO2<90% group and the SpO2≥90% group may be biased. We declare no competing interests. .. Onset of symptom to admission 6.0(4.0-9.0) 6.0(4.0-9.0) 7.0(4. Abbreviations: COVID-19, coronavirus disease 2019. Data are n/N (%), where N is the total number of patients with available data. P values are comparing the arbidol-treated group and the arbidol-untreated group from χ² test. P < 0.05 was considered statistically significant. Title: Age distribution of 69 enrolled patients with coronavirus disease 2019 (COVID-19). Legend: Number of hospital admissions by age group. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia A Novel Coronavirus from Patients with Pneumonia in China Clinical features of patients infected with 2019 novel coronavirus in Wuhan Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama 2020. 6. National health commission of China. Guideline of management of COVID-19 Clinical efficacy of arbidol (umifenovir) in the therapy of influenza in adults: preliminary results of the multicenter double-blind randomized placebo-controlled study ARBITR Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster A cluster of cases of severe acute respiratory syndrome in Hong Kong A major outbreak of severe acute respiratory syndrome in Hong Kong Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome DPP4, the Middle East Respiratory Syndrome Coronavirus Receptor, is Upregulated in Lungs of Smokers and Chronic Obstructive Pulmonary Disease Patients. Clinical infectious diseases : an official publication of the Another Decade, Another Coronavirus. The New England journal of medicine